Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Université Paris—sud

Assistance Publique-Hopitaux De Paris

Institut Gustave Roussy

Université Paris-Saclay

Hopital Marie Lannelongue

Adpuerivitam

Samir Messaoudi

Mouad Alami

Jean-Daniel Brion

Gilles Galvani

Jérôme Bignon

Marc Humbert

Olivier Provot

Gilles Bru-Mercier

Sylvia Cohen-Kaminsky

Joanna Bakala

Abdallah Hamze

Sébastien Apcher

Sebastien Dumas

Romain Darrigrand

Joëlle Dubois

Jian-Miao Liu

Zafiarisoa Dolor Renko

Mouâd Alami

Sabrina Touchet

Olivier Dulac

Svetlana Gataullina

Mohamed-Ali Soussi

Caroline Nous

Joanna Bakala-Wdzieczak

Sébastien Dumas

Jean-François Peyrat

Anne Giraud

Valérie Salgues

Jean Daniel Brion

Expedite Yen-pon

Expedite Yen-Pon

The present invention relates to the fields of medicine and in particular cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cells, in particular cancer cells, or changing the immunopeptidome, in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a therapy in a subject in need thereof. The invention also discloses methods for treating a disease, in particular cancer, for preventing or treating cancer metastasis and/or cancer recurrence, in a subject. The present invention in addition provides kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.

Madrasin-derivative compounds, composition and uses thereof for treating cancer

The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists. 

Dizocilpine derivatives as peripheral NMDA receptor antagonists

The present invention relates to the field of prevention and treatment of diseases involving NMDA receptors of the central nervous system. It relates more specifically to compounds of 1-(indol-3-yl)-3-hydroxy-3-(2-oxo-2-ethyl)-indol-2-ones type, as a drug, and the use of such compounds in the preparation of pharmaceutical compositions. These pharmaceutical compositions may in particular be intended to prevent or treat diseases involving NMDA receptors of the central nervous system, in particular severe/resistant epilepsy and cognitive disorders resulting therefrom, especially autism, but also strokes, schizophrenia, degenerative diseases involving the activation of NMDA receptors, such as Parkinson's disease and Alzheimer's disease, Rett syndrome, or amyotrophic lateral sclerosis, migraine, dementia and major depressive disorder.

NMDA receptor modulators, compositions comprising same and use of these compounds in the treatment of diseases involving the central nervous system

The invention relates to compounds which are inhibitors of the polymerization of tubulin, to the methods for the production thereof, and to the uses of same.

Cytotoxic compounds which are inhibitors of the polymerisation of tubulin

The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists. 

Adamantane and memantine derivatives as peripheral NMDA receptor antagonists

The invention relates to a compound of the formula (I) in which: R, Rand Rare independently a methoxy group optionally substituted by one or more fluorine atoms; Ris a hydrogen atom; Rand Rare identical and each represent a hydrogen or fluorine atom; A is a cycle selected from the group including aryl and heteroaryl groups, wherein said groups can be substituted.

Iso CA-4 and analogues thereof as potent cytotoxic agents inhibiting tubuline polymerization

Growing community of inventors

Chilly Mazarin, France

Samir Messaoudi